5-years RFS and prognostic factors study in HR-positive HER2-negative breast cancer patients treated with neoadjuvant endocrine therapy: Pooled analysis of two phase II trials.

Congress : EPICLIN

Authors : F Lerebours, M Pulido, E Fourme, M Debled, V. Becette, H. Bonnefoi, S. Rivera, G. Mac Grogan, MA Mouret-Reynier,  C. Tunon de Lara, JY Pierga, C Breton Callu, L Venat-Bouvet, S Mathoulin-Pélissier, P Kerbrat, F Dalenc, B. Sigal, T Bachelot, J Lemonnier, N Quenel-Tueux.

Experts group or program : French Breast Cancer Intergroup (UCBG).

Few data are available on survival of breast cancer (BC) patients (pts) treated with neoadjuvant endocrine therapy (NET). Understanding how tumor response to NET is related to relapse risk would help clinicians make decisions about additional treatments for these pts.

En savoir plus